ADALTA

adalta-logo

AdAlta Pty Ltd (AdAlta) is a Melbourne based biotech company discovering and developing protein based therapeutics. AdAlta aims to provide an alternative approach to drug discovery by finding novel shark antibody or i-body drug candidate agents for various disease conditions. AdAlta has significant expertise and proprietary libraries that will enable the discovery and identification of lead candidates. AdAlta can rapidly identify high quality binders from it's i-body or shark antibody libra... ries. A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane spanning proteins. AdAlta’s proprietary discovery technology is particularly well suited to approach this class of drug-targets that formerly was inaccessible to most protein-binder platforms. AdAlta is focused on building a pipeline of therapeutics against clinically validated targets that demonstrate significant advantages over currently marketed protein products. AdAlta also conducts collaborative and contract research. Our approach allows us to leverage the diversity of the AdAlta libraries and apply it to collaborators targets. AdAlta has a number of collaborations with research organization, biotech and pharma companies.

#SimilarOrganizations #People #Financial #Website #More

ADALTA

Social Links:

Industry:
Biotechnology Health Care Wellness

Founded:
2010-01-01

Address:
Bundoora, Victoria, Australia

Country:
Australia

Website Url:
http://www.adalta.com.au

Total Employee:
101+

Status:
Active

Contact:
+61394795159

Email Addresses:
[email protected]

Total Funding:
3 M AUD

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta WordPress Google Analytics Google Maps Content Delivery Network Font Awesome Global Site Tag HSTS Google Universal Analytics


Similar Organizations

allos-therapeutics-logo

Allos Therapeutics

Allos Therapeutics is a biopharmaceutical company that develops and commercializes anti-cancer therapeutics.

lutris-pharma-logo

Lutris Pharma

Lutris Pharma develops drugs to improve anti-cancer therapy effectiveness.

orteq-logo

Orteq

Orteq is a medical device company that develops and commercializes bioengineering solutions for orthopaedic injuries.


Current Advisors List

liddy-mccall_image

Liddy McCall Board Observer @ AdAlta
Board_observer

james-williams_image

James Williams Board Member @ AdAlta
Board_member

Current Employees Featured

michael-foley_image

Michael Foley
Michael Foley CSO @ AdAlta
CSO

samantha-cobb_image

Samantha Cobb
Samantha Cobb Founder @ AdAlta
Founder

tim-oldham_image

Tim Oldham
Tim Oldham CEO & Managing Director @ AdAlta
CEO & Managing Director
2019-10-01

david-rhodes_image

David Rhodes
David Rhodes Chief Operating Officer @ AdAlta
Chief Operating Officer

ebony-fietz_image

Ebony Fietz
Ebony Fietz Project Manager @ AdAlta
Project Manager

Founder


samantha-cobb_image

Samantha Cobb

Stock Details


Company's stock symbol is ASX:1AD

Investors List

yuuwa-capital_image

Yuuwa Capital

Yuuwa Capital investment in Series A - AdAlta

brisbane-angels_image

Brisbane Angels

Brisbane Angels investment in Series A - AdAlta

Official Site Inspections

http://www.adalta.com.au

  • Host name: sau-e9713-or.servercontrol.com.au
  • IP address: 118.127.60.243
  • Location: Doncaster Australia
  • Latitude: -37.7855
  • Longitude: 145.1202
  • Timezone: Australia/Melbourne
  • Postal: 3108

Loading ...

More informations about "AdAlta"

AdAlta - Crunchbase Company Profile & Funding

Contact Email [email protected]; Phone Number +61394795159; AdAlta Pty Ltd (AdAlta) is a Melbourne based biotech company discovering and developing protein based …See details»

Developing i-body drugs to treat fibrotic diseases - AdAlta

Based in Melbourne, AdAlta is led by an experienced management team and Board and is supported by a world class scientific advisory board. Home; About Us. AdAlta at a glance; …See details»

Corporate Governance - AdAlta - Developing i-body drugs to treat ...

The Board of Directors of AdAlta Limited is responsible for the corporate governance of the economic entity and guides and monitors the business and affairs of the Company on behalf of …See details»

Developing i-body drugs to treat fibrotic diseases - AdAlta

AdAlta Limited. Registered Address: Room 204, LIMS2 La Trobe Institute of Molecular Science Science Drive La Trobe University VIC 3086 Australia. ABN: 92 120 332 925 Ph: +61 3 9479 …See details»

AdAlta - businessabc.net

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is …See details»

AdAlta Company Profile - Office Locations, Competitors, Revenue …

Oct 28, 2024 AdAlta has 5 employees across 2 locations and $1.74 m in annual revenue in FY 2024. See insights on AdAlta including office locations, competitors, revenue, financials, …See details»

ASX Announcement/Press Release | 20 November 2024 AdAlta …

AdAlta Limited (ASX:1AD) Media & Investor Enquiries Tim Oldham The Capital Network CEO & Managing Director Julia Maguire P: +61 3 9479 5159 P: +61 2 7257 7338 E: …See details»

AdAlta Ltd Announces New Address and Strategic Growth

Jun 18, 2024 AdAlta Ltd. (AU:1AD) has released an update.AdAlta Limited, a Melbourne-based clinical stage drug development company, has announced a change in its registered office and …See details»

Long Shortz with AdAlta: The East to West vision for immunotherapy

Feb 11, 2025 Stockhead’s Fraser Palamara chats with AdAlta (ASX:1AD) managing director Tim Oldham to get the short end of the long story on the company’s latest news.. The company …See details»

AdAlta prioritises ‘East to West’ cellular immunotherapy strategy …

Feb 6, 2025 Special Report: AdAlta has ranked its East to West cellular immunotherapy strategy as its core growth priority, saying that it is the key driver of future pipeline growth and value …See details»

Management Team - AdAlta - Developing i-body drugs to treat …

AdAlta’s management team has been responsible for the development of the i-body technology platform, including the identification and pre-clinical development of the lead i-body drug …See details»

Adalta - AdAlta to Present Its i-body Next Generation Antibody …

AdAlta CEO to outline 2021 objectives for AD-214, the GE Healthcare collaboration and the new internal and external assets to be added to the pipeline. AdAlta is conducting Phase 1 clinical …See details»

Announcements | AdAlta investor hub

Back to . AdAlta. Price sensitive Periodic reports With summary. Date range. Date range. Clear dates. Apply date range. Filters. Sort by. Latest Most popular. 10. 0 results. Showing 0 to 0 of …See details»

AdAlta Strengthens Leadership for Cancer and Fibrosis Therapies

Oct 23, 2024 AdAlta Ltd. (AU:1AD) has released an update.AdAlta Limited is bolstering its leadership team with the appointment of Kevin Lynch as Consultant Chief Medical Officer for …See details»

AdAlta Presentation at The Stock Network's ASX Gems

AdAlta's (ASX:1AD) Chief Executive Officer and Managing Director Tim Oldham presented at The Stock Network's Gems Conference on Friday, 22 March 2024.Tim's presentation provided an …See details»

StockTake: AdAlta - Gold Coast Bulletin

2 days ago AdAlta (ASX:1AD) has built on a deal with SYNthesis BioVentures Fund One, which plans to invest $500,000 in seed funding for its subsidiary AdCella, with a total commitment of …See details»

The i-body platform - AdAlta - Developing i-body drugs to treat ...

Identifying and developing new i-body therapeutics AdAlta has utilised the unique structure of the i-body to develop a proprietary library containing over 20 billion i-body compounds. The library …See details»

ASX:1AD - Letter to Shareholders, Notice of AGM & Proxy Form

Back to . AdAlta. Letter to Shareholders, Notice of AGM & Proxy Form. Released 17 Oct 24. Q&As Share. Follow. Latest announcements. Open panel View summary and Q&As. Ask a …See details»

AdAlta Unit to Receive Seed Investment of Up to AU$2 Million, …

3 days ago AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9% 23-11-07: MT AdAlta to Seeks AU$1.2 Million from Share Placement 23-11-03: MT AdAlta …See details»

AdAlta and Carina Biotech to develop next-generation i-body …

AdAlta (ASX:1AD) and Carina Biotech join forces to develop next-generation CAR-T cancer therapeutics CAR-T therapy explained Chimeric antigen receptor T cell (CAR-T) therapy is a …See details»

linkstock.net © 2022. All rights reserved